GleamWall
中文EN

RZLT Rezolute, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1509261 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.9%
ROA-61.2%
ROIC (approx.)-60.4%
Asset turnover—

Leverage & solvency

Liabilities / assets10.5%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue——
R&D expense$53.80M$61.53M
SG&A expense$29.17M$18.37M
Operating income-$82.97M-$79.89M
Income tax$0$0
Net income-$77.59M-$74.41M
EBITDA-$82.94M-$79.86M
EPS (basic)-0.75-0.98
EPS (diluted)-0.75-0.98
Weighted avg. shares (diluted)103.91M76.00M
Balance sheet
Cash & equivalents$10.62M$94.11M
Short-term investments$97.19M$73.75M
Current assets$110.51M$171.15M
PP&E, net$41,000$72,000
Total assets$112.85M$175.49M
Current liabilities$11.42M$11.91M
Total liabilities$12.16M$13.36M
Shareholders' equity$100.69M$162.13M
Shares outstanding96.41M87.00M
Cash flow statement
Operating cash flow-$64.64M-$69.08M
Investing cash flow-$21.10M-$14.54M
Financing cash flow$2.24M$107.33M
Depreciation & amortization$31,000$31,000
Stock-based compensation$14.46M$7.12M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.